Gudin J. Effect of physical manipulation on the oral pharmacokinetic profile of Xtampza® ER (oxycodone DETERx® formulation): A review of published studies. J Opioid Manag. 2020;16(2):127?139. doi:10.5055/jom.2020.0559
Pub Category: Abuse Deterrence
Meske D, Kopecky EA, Passik S, Shram MJ. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER). J Opioid Manag. 2018;14(5):359?372. doi:10.5055/jom.2018.0468
Fleming AB, Mayock SP, Saim S. Response to Crudele et al. Commentary on Mayock et al. “In Vitro Drug Release after Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations”. Clin Drug Investig. 2018;38(8):799?800. doi:10.1007/s40261-018-0664-y
Crudele N, Giordano J. Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations. Clin Drug Investig. 2018;38(8):795?797. doi:10.1007/s40261-018-0663-z
Mayock SP, Saim S, Fleming AB. Author Correction to: In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations. Clin Drug Investig. 2017;37(12):1203. doi:10.1007/s40261-017-0599-8
Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza® ER and Other ER Opioid Formulations [published correction appears in Clin Drug Investig. 2017 Dec;37(12 ):1203]. Clin Drug Investig. 2017;37(12):1117?1124. doi:10.1007/s40261-017-0561-9
Brennan MJ, Kopecky EA, Marseilles A, O’Connor M, Fleming AB. The comparative pharmacokinetics of physical manipulation by crushing of Xtampza® ER compared with OxyContin®. Pain Manag. 2017;7(6):461?472. doi:10.2217/pmt-2017-0030
Kopecky EA, Fleming AB, Levy-Cooperman N, O’Connor M, M Sellers E. Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER). J Clin Pharmacol. 2017;57(4):500?512. doi:10.1002/jcph.833
Webster LR, Kopecky EA, Smith MD, Fleming AB. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Pain Med. 2016;17(6):1112?1130. doi:10.1093/pm/pnv020
Fleming AB, Scungio TA, Grima MP, Mayock SP. In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. J Opioid Manag. 2016;12(1):57?65. doi:10.5055/jom.2016.0312